First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma (RCC): An international multi-center study.
Talal El Zarif(Yale University), Toni K. Choueiri(Harvard University), Bohuslav Melichar(Palacký University Olomouc), Sebastiano Buti(University of Parma), Marco Stellato(Università Campus Bio-Medico), Anežka Zemánková(Palacký University Olomouc), Ajjai Alva(Michigan Medicine), Karl Semaan(Broad Institute), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Charles B. Nguyen(Michigan Medicine), Catherine C. Fahey(University of North Carolina at Chapel Hill), Wanling Xie(Dana-Farber Cancer Institute), Sumanta Kumar Pal(City of Hope), José A. Karam(The University of Texas MD Anderson Cancer Center), Hedyeh Ebrahimi(City of Hope), Balaji Venugopal(Beatson West of Scotland Cancer Centre), Daniel Yick Chin Heng(University of Calgary), Martín Zarbá(University of Calgary), Katy Beckermann(Vanderbilt University Medical Center), Matthew T. Campbell(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k